: ‘Tripledemic’ demand for Motrin and Tylenol fueled year-end sales in J&J’s consumer business

0
3

As cases of COVID, flu and respiratory syncytial virus surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson’s JNJ consumer health business.

J&J’s over-the-counter division, which includes the pain reliever Motrin and the allergy medicine Zyrtec, had sales of $1.57 billion in the final three months of 2022, up from $1.37 billion in the same quarter of the previous year. It also beat the FactSet consensus of $1.40 billion. (The company does…

Market Watch

Read More